The US Government Accountability Office has reported that Medicare Advantage plans made $1.3 billion profit above forecasts in 2006. It also found that private providers of Medicare coverage cost the federal government 13% more than the publicly-provided system. Insurers reported a profit margin of 6.6% versus the 4.1% which had been projected. This appears to be explained by the lower than expected proportion of spending on medical expenses. These findings are consistent with the experience of the Part D prescription drug program, which also reported reduced costs, partly due to effective pricing negotiations by pharmacy benefit managers, but also due to a smaller number of subsidized low-income beneficiaries than anticipated.
The GAO report led the Chairman of the House of Representatives' Ways and Means Health Subcommittee, Pete Stark (Democrat, California), to claim that the GAO has "put to bed this idea [that] the plans are offering extra benefits with the overpayments."
Since the introduction of the Medicare Modernization Act in 2002, Democrats have made repeated attempts to limit or scrap the Medicare Advantage program (Marketletters passim), which they argue, provide subsidies to private health care insurers and fail to deal with the uninsured population of the USA, which ranges from over 40 million to about 60 million people, depending on the definition used. One of the key attractions of some Advantage plans are those that provide coverage for prescription drugs during the Part D "Donut hole" gap, which in 2006 concerned medicine expenses between $2,250 and $5,100.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze